AMENDMENTS

This listing replaces all prior versions and listings of claims in the application.

1. (Currently amended) A stable liquid medical formulation~~, which contains~~ (A) that comprises a therapeutically effective amount of an antibody ~~in a glutamate buffer~~ against CD40, sorbitol as isotonizing agent, a polysorbate as surfactant and glutamate as sole buffer and (B) that has a pH between 4.0 and 6.0.

2. (Currently amended) The stable liquid medical formulation according to claim 1, wherein the concentration of the buffer is between 1 mM and 50 mM.

3. (Canceled)

4. (Currently amended) The stable liquid medical formulation according to claim [[3]] 1, which contains no salt as an isotonizing agent.

5-6. (Canceled)

7. (Currently amended) The stable liquid medical formulation according to ~~any one of claims 3 to 6~~ claim 1, ~~wherein the~~ having an osmotic pressure [[is]] between 250 mOsm and 350 mOsm.

8. (Canceled)

9. (Currently amended) The stable liquid medical formulation according to claim [[8]] 1, wherein the surfactant is polysorbate 80.

10. (Currently amended) The stable liquid medical formulation according to claim ~~8 or 9~~ 1, wherein the ~~concentration of the~~ surfactant [[is]] is present in a concentration between 0.02 mg/mL and 0.10 mg/mL.

11. (Currently amended) The stable liquid medical formulation according to claim 1, wherein the antibody against CD40 is a human antibody, a humanized antibody, or a chimeric antibody.

12. (Currently amended) The stable liquid medical formulation according to claim 1, wherein the antibody against CD40 is a monoclonal antibody.

13. (Currently amended) The stable liquid medical formulation according to claim 1, wherein the antibody against CD40 is IgG.

14. (Currently amended) The stable liquid medical formulation according to claim 13, wherein the IgG ~~subclass~~ is any one of IgG1, IgG2, or IgG4.

15-17. (Canceled)

18. (Currently amended) The stable liquid medical formulation according to claim 1, wherein the antibody against CD40 is present in a concentration between approximately 1 and 200 mg/mL.

19-20. (Canceled)

21. (Currently amended) The stable liquid medical formulation ~~according to any one of claims 1, 19 or 20, which contains~~ comprising:

(a) a therapeutically effective amount of an antibody against CD40;

(b) sorbitol as isotonizing agent;

(c) a polysorbate as surfactant; and

(d) at least one stabilizing agent selected from the group consisting of glycine, methionine, cysteine hydrochloride, leucine, lysine hydrochloride, arginine hydrochloride, aspartic acid, ascorbic acid, EDTA, and salts thereof,

with glutamate as sole buffer, the formulation having a pH between 4.0 and 6.0.

22-23. (Canceled)